Biotech Aeglea BioTherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) December 2, 2022
Biotech INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Eiger BioPharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm December 2, 2022
Biotech EIGR Investors Have Opportunity to Lead Eiger BioPharmaceuticals, Inc. Securities Fraud Lawsuit December 2, 2022
Biotech Bronstein, Gewirtz & Grossman, LLC, A Successful Firm, Notifies Eiger BioPharmaceuticals, Inc. (EIGR) Investors of Class Action and Encourages Investors to Actively Participate December 2, 2022
Biotech EIGR SHAREHOLDER ALERT: Jakubowitz Law Reminds Eiger Shareholders of a Lead Plaintiff Deadline of January 9, 2023 December 2, 2022
Biotech ANAVEX®2-73 (Blarcamesine) Phase 2B/3 Study Met Primary and Key Secondary Endpoints, Showing Statistically Significant Reduction of Clinical Decline in Global Clinical Study of Patients With Early Alzheimer’s Disease December 1, 2022
Search
life sciences
December 2, 2022
December 2, 2022
December 2, 2022
December 2, 2022
December 2, 2022
December 2, 2022
December 2, 2022
December 2, 2022
December 2, 2022
December 1, 2022
